시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 골형성부전증 치료 시장 보고서(2025년)
Osteogenesis Imperfecta Treatment Global Market Report 2025
상품코드 : 1769692
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,310,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,121,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,932,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

골형성부전증 치료 시장 규모는 향후 수년간 안정적인 성장이 예상될 것으로 예측됩니다. 예상 성장 요인에는 골형성부전증(OI) 환자의 증가, 유전성 질환에 대한 인식 개선 및 진단율 향상, 골 건강을 표적으로 한 효율적인 치료법 수요 급증, 희귀 질환 치료 연구에 대한 자금 지원 확대, 단일클론 항체 개발 분야의 혁신 등이 포함됩니다. 예측 기간 동안 예상되는 주요 동향으로는 단일 클론 항체 공학의 발전, 3D 뼈 진단 및 영상 기술의 혁신, 첨단 의약품 전달 메커니즘의 획기적인 발전, 진화하는 줄기 세포 및 재생 치료 솔루션, 원격 환자 관리를 위한 원격 의료 플랫폼의 채택 확대 등이 있습니다.

골형성부전증의 유병률이 증가하면서 골형성부전증 치료 시장이 크게 성장하고 있습니다. 제 1형 콜라겐의 결함이나 부족으로 인해 뼈가 쉽게 부러지는 것이 특징인 이 유전적 질환은 유전자 검사의 발전과 진단 인식의 제고로 인해 점점 더 많이 발견되고 있습니다. 이러한 발전으로 인해 이전에는 진단되지 않았던 사례들이 확인되고 있습니다. 골형성부전증의 치료는 뼈를 강화하고, 골절의 위험을 줄이며, 증상을 관리하고, 환자의 이동성과 전반적인 삶의 질을 개선하는 데 중점을 둡니다. 예를 들어, 2022년 6월 영국 의회는 영국에서 약 5,000명이 골형성부전증에 걸려 있다고 보고했습니다. 따라서 진단 사례의 증가가 시장 성장을 촉진하는 데 중요한 역할을 하고 있습니다.

골형성부전증 치료제 시장은 환자의 골 형성을 촉진하고 골절 위험을 최소화하기 위해 스클레로스틴 억제 요법 등 첨단 치료법에 점점 더 집중하고 있습니다. 이 접근법은 단일 클론 항체를 사용하여 뼈의 성장을 억제하는 단백질인 스클레로스틴을 차단하여 뼈의 미네랄 밀도와 강도를 높입니다. 예를 들어, 2024년 10월, 미국에 본사를 둔 바이오 제약 회사인 Ultragenyx Pharmaceutical Inc.는 자사의 임상 시험용 의약품인 세트루수맙(UX143)에 대해 FDA로부터 획기적 치료제 지정을 받았습니다. Setrusumab은 스클레로스틴을 억제하여 새로운 뼈의 성장을 촉진하고 뼈의 강도를 개선하여 2세 이상의 제1형, 제3형 및 제4형 골형성부전증 환자의 골절 위험을 감소시키기 위해 설계된 완전 인간 단일 클론 항체입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Osteogenesis imperfecta treatment involves a comprehensive approach encompassing medical, surgical, and supportive care strategies to manage symptoms, enhance bone strength, minimize the risk of fractures, and improve the overall quality of life for individuals living with osteogenesis imperfecta (OI), a hereditary condition marked by fragile bones.

The primary treatment options for osteogenesis imperfecta include medication, surgery, physical therapy, and lifestyle changes. Medications involve the administration of pharmaceutical agents to treat or manage medical conditions. In the context of OI, drugs such as bisphosphonates, teriparatide, and monoclonal antibodies are utilized to fortify bones and lower the likelihood of fractures. These medications fall into categories such as teriparatide, denosumab, among others, and are administered through various routes, including subcutaneous, intravenous, and oral methods. Distribution occurs through hospital pharmacies, retail pharmacies, and online platforms, serving a range of end users like hospitals, homecare services, specialized clinics, and other medical facilities.

The osteogenesis imperfecta treatment market research report is one of a series of new reports from The Business Research Company that provides osteogenesis imperfecta treatment market statistics, including the osteogenesis imperfecta treatment industry's global market size, regional shares, competitors with the osteogenesis imperfecta treatment market share, detailed osteogenesis imperfecta treatment market segments, market trends and opportunities, and any further data you may need to thrive in the osteogenesis imperfecta treatment market. This osteogenesis imperfecta treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteogenesis imperfecta treatment market size has grown steadily in recent years. It will grow from $0.89 billion in 2024 to $0.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. Factors contributing to this historical growth include a rise in clinical trials focused on OI-specific medications, increased spending on rare disease healthcare, enhanced emphasis on personalized and regenerative treatments, broader access to genetic screening and counseling services, and strengthened partnerships between pharmaceutical and biotechnology firms.

The osteogenesis imperfecta treatment market size is expected to see steady growth in the next few years. It will grow to $1.11 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. Projected growth drivers include a rising number of OI cases, improved awareness and diagnostic rates of genetic conditions, surging demand for efficient therapies targeting bone health, expanded funding for research in rare disease treatment, and increased innovation in monoclonal antibody development. Key trends anticipated during the forecast period include progress in monoclonal antibody engineering, innovations in 3D bone diagnostic and imaging technologies, breakthroughs in advanced drug delivery mechanisms, evolving stem cell and regenerative treatment solutions, and greater adoption of telehealth platforms for managing patients remotely.

The rising prevalence of osteogenesis imperfecta is contributing significantly to the growth of the osteogenesis imperfecta treatment market. This genetic disorder, characterized by fragile bones that break easily due to defective or insufficient type I collagen, is being detected more frequently owing to improved genetic testing and heightened diagnostic awareness. These advancements have led to the identification of cases that were previously undiagnosed. Treatments for osteogenesis imperfecta focus on strengthening bones, reducing the risk of fractures, managing symptoms, and improving patients' mobility and overall quality of life. For example, in June 2022, the Parliament of the United Kingdom reported that approximately 5,000 people in the UK were affected by osteogenesis imperfecta. As such, the increasing number of diagnosed cases is playing a key role in driving market growth.

Companies in the osteogenesis imperfecta treatment market are increasingly focusing on advanced therapeutics, such as sclerostin inhibition therapy, to enhance bone formation and minimize the risk of fractures in patients. This approach uses monoclonal antibodies to block sclerostin, a protein that inhibits bone growth, thereby boosting bone mineral density and strength. For instance, in October 2024, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company based in the United States, received Breakthrough Therapy Designation from the FDA for its investigational drug setrusumab (UX143). Setrusumab is a fully human monoclonal antibody designed to inhibit sclerostin, encouraging new bone growth and improving bone strength to reduce the risk of fractures in patients with Types I, III, and IV of osteogenesis imperfecta aged two years and older.

In June 2022, Sirana Pharma GmbH, a biotechnology company based in Germany, entered into a collaboration with Pfizer Inc. to develop and validate new drug candidates aimed at the regenerative repair of muscle and bone tissue affected by osteogenesis imperfecta. This initiative utilizes Sirana's proprietary microRNA-targeting platform. Pfizer Inc., a US-based pharmaceutical firm, is known for its wide-ranging treatments in areas such as vaccines, oncology, internal medicine, and rare diseases.

Major players in the osteogenesis imperfecta treatment market are Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Cipla Ltd., BioMarin Pharmaceutical Inc., Stada Arzneimittel AG, Alkem Laboratories Ltd., Ultragenyx Pharmaceutical Inc., OrthoPediatrics Corp., Ascendis Pharma A/S, Pfenex Inc., Mereo BioPharma Group PLC, and BioSenic SA.

North America was the largest region in the osteogenesis imperfecta treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in osteogenesis imperfecta treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the osteogenesis imperfecta treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteogenesis imperfecta treatment market consists of revenues earned by entities by providing services such as physical therapy, occupational therapy, and orthopedic support. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteogenesis imperfecta treatment market also includes sales of bisphosphonates, intramedullary rods, and braces and splints. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteogenesis Imperfecta Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteogenesis imperfecta treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for osteogenesis imperfecta treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteogenesis imperfecta treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Osteogenesis Imperfecta Treatment Market Characteristics

3. Osteogenesis Imperfecta Treatment Market Trends And Strategies

4. Osteogenesis Imperfecta Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Osteogenesis Imperfecta Treatment Growth Analysis And Strategic Analysis Framework

6. Osteogenesis Imperfecta Treatment Market Segmentation

7. Osteogenesis Imperfecta Treatment Market Regional And Country Analysis

8. Asia-Pacific Osteogenesis Imperfecta Treatment Market

9. China Osteogenesis Imperfecta Treatment Market

10. India Osteogenesis Imperfecta Treatment Market

11. Japan Osteogenesis Imperfecta Treatment Market

12. Australia Osteogenesis Imperfecta Treatment Market

13. Indonesia Osteogenesis Imperfecta Treatment Market

14. South Korea Osteogenesis Imperfecta Treatment Market

15. Western Europe Osteogenesis Imperfecta Treatment Market

16. UK Osteogenesis Imperfecta Treatment Market

17. Germany Osteogenesis Imperfecta Treatment Market

18. France Osteogenesis Imperfecta Treatment Market

19. Italy Osteogenesis Imperfecta Treatment Market

20. Spain Osteogenesis Imperfecta Treatment Market

21. Eastern Europe Osteogenesis Imperfecta Treatment Market

22. Russia Osteogenesis Imperfecta Treatment Market

23. North America Osteogenesis Imperfecta Treatment Market

24. USA Osteogenesis Imperfecta Treatment Market

25. Canada Osteogenesis Imperfecta Treatment Market

26. South America Osteogenesis Imperfecta Treatment Market

27. Brazil Osteogenesis Imperfecta Treatment Market

28. Middle East Osteogenesis Imperfecta Treatment Market

29. Africa Osteogenesis Imperfecta Treatment Market

30. Osteogenesis Imperfecta Treatment Market Competitive Landscape And Company Profiles

31. Osteogenesis Imperfecta Treatment Market Other Major And Innovative Companies

32. Global Osteogenesis Imperfecta Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osteogenesis Imperfecta Treatment Market

34. Recent Developments In The Osteogenesis Imperfecta Treatment Market

35. Osteogenesis Imperfecta Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기